- Home
- SQFT vs XRTX Comparison
SQFT vs XRTX Comparison
Compare SQFT & XRTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SQFT | XRTX |
|---|---|---|
| Founded | 1999 | 2011 |
| Country | United States | Canada |
| Employees | 15 | N/A |
| Industry | Real Estate Investment Trusts | Pharmaceuticals and Biotechnology |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.7M | 4.3M |
| IPO Year | N/A | 2018 |
Fundamental Metrics
Financial Performance| Metric | SQFT | XRTX |
|---|---|---|
| Price | $3.30 | $2.21 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 25.9K | ★ 61.3K |
| Earning Date | 05-13-2026 | 05-15-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.10 | $0.35 |
| 52 Week High | $23.00 | $3.60 |
Technical Indicators
Market Signals| Indicator | SQFT | XRTX |
|---|---|---|
| Relative Strength Index (RSI) | 49.57 | 46.82 |
| Support Level | $3.13 | $1.98 |
| Resistance Level | $3.91 | $3.03 |
| Average True Range (ATR) | 0.29 | 0.28 |
| MACD | -0.04 | -0.10 |
| Stochastic Oscillator | 39.82 | 23.42 |
Price Performance
Historical ComparisonAbout SQFT Presidio Property Trust Inc.
Presidio Property Trust Inc is an internally managed, diversified REIT with holdings in model home properties which are triple-net leased to homebuilders, office, industrial, and retail properties. Presidio's model homes are leased to homebuilders located in Arizona, Illinois, Texas, Wisconsin, and Florida. The office, industrial and retail properties are located in Colorado, with properties also located in Maryland, North Dakota, Texas, and Southern California.
About XRTX XORTX Therapeutics Inc.
XORTX Therapeutics Inc is a clinical-stage pharmaceutical company focused on developing therapies to treat gout and progressive kidney disease modulated by aberrant purine and uric acid metabolism in orphan disease indications such as allopurinol-intolerant gout and autosomal dominant polycystic kidney disease, as well as more prevalent type 2 diabetic nephropathy and fatty liver disease. Its focus is on developing products to slow and/or reverse the progression of these diseases. The Company operates in one reportable operating segment: the development and commercialization of therapies to treat hyperuricemia-related diseases.